What Pharmacists Should Know About Traveler's Diarrhea

Jai Radhakrishnan, MD, discusses why IgG4-related kidney disease is often missed and what MITIGATE subgroup data presented at ASN Kidney Week 2026 show

Real-world data from ASN Kidney Week show GLP-1 RA users with CKD and obesity had lower rates of kidney failure, death, and heart failure exacerbation.

Hiddo J. L. Heerspink, PharmD, PhD, discusses SOLSTICE elecoglipron data, finerenone in FSGS, and glucagon’s kidney effects from ASN Kidney Week 2026.

Pharmacy performance measures should recognize clinical interventions, patient counseling, prescriber collaboration, and outcomes—not prescription volume alone.

CMS’s GLP-1 Bridge demo bypasses Part D to cover select obesity drugs, with a $50 monthly copay, PA workflow, and strict eligibility through 2027.

Two Kidney Week 2026 analyses tie SGLT2 inhibitors to kidney, CV, and survival gains in T2D, yet over half of patients with diabetic CKD receive neither.

Two Kidney Week 2026 abstracts show a dose-response link between cardiovascular-kidney-metabolic syndrome (CKM) stage and chronic kidney disease (CKD), while primary care clinicians cite evidence and workflow barriers.

In more than 262,000 UK Biobank participants, a 5-marker cardiometabolic score was linked to graded risk at each step toward CKM multimorbidity.